Online BusinessSuven gets 3 European patents on NCEs
Suven Life Sciences Limited, a Hyderabad-based biopharmaceutical company specialising in central nervous system (CNS) diseases, has received patents corresponding to three new chemical entities (NCEs) for the treatment of disorders associated with neuro-degenerative diseases.
- Suven Life Sciences, Gammon India & Pyramid Saimira Q2 results - Suven Life Sciences granted patents in 9 markets - Suven Life Sciences to raise $50 mn via securities - Suven Life gets two more US patents for NCEs - Suven Life"s drug discovery achieves milestone - Suven in talks with global drug makers for licensing deal: CEO
The patents, valid up to 2022, 2023 and 2024 respectively, were granted by the European Patent Office (EPO). With these new patents, Suven now has 7 granted EPO patents on NCEs, which have been validated in the 37 member countries in Europe.
The newly granted claims of the patents include the class of selective 5-HT compounds discovered by Suven and are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neuro-generative disorders like Alzheimer’s, Parkinson, schizophrenia, Huntington’s disease and attention-deficit hyperactivity disorder (ADHD).
“Our pipeline of molecules in the CNS arena that are being developed for cognitive disorders has an estimated $20 billion market potential globally,” Venkat Jasti, chief executive of Suven, stated in a press release on Monday.
Suven Life currently has six internally-discovered therapeutic drug candidates, which are in pre-clinical stage of development targeting conditions such as ADHD, dementia, depression and Huntington’s disease.
The company’s scrip is currently trading at Rs 25.85 on the BSE, up 4.87 per cent over the previous close of Rs 24.65.